EVALUASI PEMBERIAN TRIHEKSIFENIDIL SEBAGAI PENANGANAN EXTRAPYRAMIDAL SYMPTOMS PADA PASIEN SKIZOFRENIA YANG MENERIMA HALOPERIDOL-TRIHEKSIFENIDIL DAN HALOPERIDOL-TRIHEKSIFENIDIL-KLOZAPIN DI KLINIK GRHA ATMA

• Main Author: Angela Adrianto, Felicia
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/44383
• Institution: Institut Teknologi Bandung

Schizophrenia is a severe mental disorder which affects 21 million people worldwide and around 400.000 Indonesians. Antipsychotics are used to treat the symptoms of schizophrenia. The use of antipsychotics can cause extrapyramidal symptoms (EPS) as the side effect. This study was aimed to determine the prescription appropriateness (based on the history of EPS), effectiveness, and costeffectiveness from the subjects receiving haloperidol (group 1), haloperidol-trihexyphenidyl (group 2), and haloperidol-trihexyphenidyl-clozapine (group 3). The prescription appropriateness analysis was done by comparing the percentage of EPS history in subjects of group 2 and group 3. The effectiveness analysis was done using a chi-square method to compare the EPS between group 1, 2, and 3 after the medication started. The cost-effectiveness analyses was done by using the incremental costeffectiveness ratio (ICER) method. From the analyses result, the percentage of the appropriate trihexyphenidyl prescription based on the EPS history was 50% for group 2 and 45,76% in group 3. Based on the effectiveness analysis, there was no correlation between the treatment given and the amount of EPS (p=0,240 at CI 95%). The ICER score for the comparation between group 2 and group 1 was -8285,9, while the comparation between group 3 and group 1 was 140939,7, and between group 3 and group 2 was 147903,23. Taken together, results of present study indicate that there was no differences in appropriateness of trihexyphenidyl prescription in group 2 and 3, and there was no significant differences in the effectiveness of the treatment in reducing the EPS, furthermore single treatment of haloperidol would have better pharmacoeconomics.